Biogen Inc. (BIIB) fair value analysis

S&P 500 & Nasdaq · Updated 2026-09-07

Biogen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers therapies for neurodegenerative diseases, immunology conditions, and other serious illnesses. The company operates globally with research, development, and manufacturing facilities across multiple continents, serving patients and healthcare providers worldwide.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, BIIB is trading at within about 10% of estimated fair value.

BIIB currently ranks #86 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $220.83
Sector: Healthcare
12-month range: $151.44–$216.04

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: B
Leverage: Low
Margin trend: Stable
Revenue growth: Modest
RSI zone: Neutral
50/200-day trend: Uptrend
52-week position: The top quarter of its range
DCF cross-check: Undervalued

What our data shows for BIIB

Our model validated 17 trailing price-to-earnings windows for BIIB, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $151.44–$216.04.
The 14-day relative strength index sits at a neutral 61.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for BIIB
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent BIIB news

TickrTrends' derived news-sentiment signal for BIIB is currently leaning positive, computed from recent coverage.

BIIB Looks 13.8% Overvalued on GF Value™ Following China Approval (gurufocus.com, 2026-09-03)
TickrTrends take: Biogen's recent China approval presents a potential revenue growth catalyst, yet the stock appears to trade at a premium to its GF Value assessment, which suggests limited upside for value-oriented investors at current levels. Given TickrTrends' Fairly valued designation, the market appears to be weighing the approval's long-term benefits against near-term valuation concerns. Investors focused on valuation metrics should monitor whether the company can deliver earnings growth sufficient to justify the current premium or if the stock price adjusts lower to better align with intrinsic value estimates.

What people are saying

Follow the BIIB conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — BIIB's momentum indicator declined this week, shifting from a grade of A to no rating, suggesting a weakening in price movement trends. The stock remains in the Healthcare sector and maintains a Fairly valued assessment based on current valuation metrics. This change in momentum tracking may warrant monitoring of the stock's near-term price action.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is BIIB stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), BIIB is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is BIIB's TickrTrends verdict?

BIIB's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does BIIB compare to other Healthcare stocks?

BIIB ranks #86 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is BIIB overbought or oversold?

BIIB's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

BIIB vs ABBV · BIIB vs BIO · BIIB vs BVS · BIIB vs JAZZ · BIIB vs LH